Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review

A Addario, T Célarier, B Bongue, N Barth, G Gavazzi… - GeroScience, 2023 - Springer
This systematic review aims to summarize the impact of vaccination against influenza,
shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the …

Immunomodulation Therapies for Atherosclerosis: The Past, the Present, and the Future

D Lecis, G Massaro, D Benedetto, M Di Luozzo… - International Journal of …, 2023 - mdpi.com
Atherosclerotic cardiovascular disease is the most common cause of morbidity and death
worldwide. Recent studies have demonstrated that this chronic inflammatory disease of the …

Multi-interfaced Ni/C@ RGO/PTFE composites for electromagnetic protection applications with high environmental stability and durability

X Yuan, L Li, Y Yan, J Wang, H Zhai, G Wan… - Journal of Colloid and …, 2024 - Elsevier
To efficiently address the growing electromagnetic pollution problem, it is urgently required
to research high-performance electromagnetic materials that can effectively absorb or shield …

Lipoprotein (a) and oxidized phospholipids: partners in crime or individual perpetrators in cardiovascular disease?

DJ Rader, A Bajaj - Journal of the American College of Cardiology, 2023 - jacc.org
It is well-established that lipoprotein (a)(Lp [a]) is a genetically determined causal risk factor
for a range of cardiovascular diseases. Large prospective population-based observational …

Atherosclerosis antigens as targets for immunotherapy

I Raposo-Gutiérrez, A Rodríguez-Ronchel… - Nature Cardiovascular …, 2023 - nature.com
Atherosclerosis is a chronic inflammatory disease of the arteries that can lead to thrombosis,
infarction and stroke, underlying the first cause of mortality worldwide. Adaptive immunity …

23-valent pneumococcal polysaccharide vaccine and the risk of renal progression in older patients with chronic kidney disease

PY Chang, CJ Lin, HC Chen, HC Fan, H Kuo - Preventive Medicine, 2023 - Elsevier
Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) ensures
favorable outcomes and reduces the risk of cardiac events in patients on dialysis. However …

The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society …

A Mamcarz, M Wełnicki, J Drożdż… - Polish Heart …, 2023 - journals.viamedica.pl
Respiratory diseases have been the fourth most common cause of death in Poland in recent
year s. Respiratory infection, especially pneumonia, can lead to exacerbation of chronic …

Znaczenie szczepień przeciwko pneumokokom w redukcji ryzyka sercowo-naczyniowego pacjentów kardiologicznych. Opinia ekspertów Komisji Profilaktyki …

A Mamcarz, M Wełnicki, J Drożdż… - Polish Heart …, 2023 - journals.viamedica.pl
Choroby układu oddechowego stały się w ostatnich latach czwartą najczęstszą przyczyną
zgonów w Polsce. Infekcja dróg oddechowych, zwłaszcza zapalenie płuc, może prowadzić …

[HTML][HTML] Persistence of Detectable Anti-Pneumococcal Antibodies 4 Years After Pneumococcal Polysaccharide Vaccination in a Randomised Controlled Trial: The …

J Attia, JC Horvat, T Hunter, PM Hansbro, A Hure… - Heart, Lung and …, 2023 - Elsevier
Aim Mouse models have indicated that the pneumococcal polysaccharide vaccine (PPV)
can reduce atherosclerosis. This is probably through a process of molecular mimicry, where …